Media Release The pivotal TACTI-004 Phase III trial in first line non-small cell lung cancer (1L NSCLC) continues to build ...

Detailed price information for Takeda Pharmaceutical Ltd ADR (TAK-N) from The Globe and Mail including charting and trades.

Media Release The pivotal TACTI-004 Phase III trial in first line non-small cell lung cancer (1L NSCLC) continues to build momentum and is recruiting patients at a growing number of activated clinical ...

A new technology that harnesses artificial intelligence (AI) to analyze mammograms and improve the accuracy of predicting a ...

Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening ...

Maria Velez, MD, a pediatric hematologist-oncologist at New Orleans-based Manning Family Children’s, has been appointed president of the American Society of Pediatric Hematology/Oncology.  The ASPHO ...

Though nerves abound for funders and founders in the industry, money continues to flow into startups, sometimes in ...

A new technology that harnesses AI to analyze mammograms and improve the accuracy of predicting a woman's personalized ...

Following a complete response letter rejecting accelerated approval for RP1 in advanced melanoma, IGNYTE trial investigators are urging the FDA to reevaluate the therapy’s robust survival data, just ...

The first commercial for Johnson & Johnson and Legend Biotech’s Carvykti focuses on the numbers that make up a multiple ...